The possibility of price competition for cancer drugs, and perhaps other drugs in the not too distant future
Author: Pierre Etienne, Co-Founder and CMO
Our first podcast focuses on the growing discontent about pharma pricing practices in the US, particularly for new agents in cancer. Recent developments in this space seem to suggest that this status-quo can expect some much needed disruption.
Chief Medical Officer and Co-founder
Pharma industry veteran with 30+ years in large Pharma & in leading small biotechs, spearheading large initiatives and securing funding, psychiatry practice and research for 10+ years.